OVX836

Phase 2Biologic

OOsivax

OVX836 is one of 18 biologic programs targeting Influenza. It is currently in Phase 2.

Indications

Total Trials

Active Trials

Competitors

Pipeline

Status by Indication[3][1]

Indication

InfluenzaActive, not recruiting

InfluenzaPhase 2

Active, not recruiting

Competition

Competitive Landscape

1053 competitors in Influenza

#DrugCompanyPhaseTrials

Fluzone

Sanofi

Preclinical

16 2

Fluzone

GSK

Preclinical

37 3

Trexall

Alnylam Pharmaceuticals

Preclinical

1 4

Crestor

AstraZeneca

Preclinical

1 5

Avigan

AAppili Therapeutics Inc.

Preclinical

6 6

Quadrivalent Influenza Vaccine

Sanofi

Preclinical

30 7

OVX836

OOsivax

Phase 2

4 8

COMIRNATY

Pfizer

Preclinical

1 9

Influenza A/H5N1

NNational Institute of Allergy and Infectious Diseases (NIAID)

Preclinical

14 10

PD-1/PD-L1 Inhibitors

CChuangzhen Chen

Preclinical

Ranked by pipeline maturity and clinical activity. Current drug highlighted in teal.

Clinical

Trials by Indication[1]

Influenza4 trials

Efficacy, Immunogenicity and Safety of OVX836 Influenza Vaccine 480μg

Active, not recruiting·OOsivax·Phase 2·NCT05569239·2,850 enrolled

Immunogenicity and Safety of the Concomitant Administration of OVX836 and Quadrivalent Influenza Vaccine in Healthy Volunteers.

Completed·OOsivax·Phase 2·NCT05284799·180 enrolled

Immunogenicity and Safety of the Concomitant Administration of OVX836 Influenza Vaccine, Quadrivalent Inactivated Influenza Vaccines and Placebo in Healthy Subjects.

Completed·OOsivax·Phase 2·NCT05734040·478 enrolled

Show 1 more trial

Safety and Immunogenicity of Two Dose Levels of OVX836 Influenza Vaccine as a Booster on Participants Previously Administered With OVX836

Completed·OOsivax·Phase 2·NCT06582277·117 enrolled

Intranasal Administration1 trial

Safety and Immune Response of Increasing Doses of OVX836 After Intramuscular or Intranasal Administrations in Healthy Subjects

Completed·OOsivax·Phase 1·NCT03594890·72 enrolled

Immune Response1 trial

Safety and Immune Response of One Dose of OVX836 at Two Dose Levels, in Comparison to Influvac TetraTM, After Intramuscular Administration in Healthy Subjects Aged 18-65 Years

Completed·OOsivax·Phase 2·NCT04192500·300 enrolled

Sources

References

[1]
ClinicalTrials.gov — 6 trial records for OVX836. U.S. National Library of Medicine, National Institutes of Health.
[2]
ChEMBL — OVX836 compound record. European Bioinformatics Institute (EMBL-EBI).
[3]
Open Targets Platform — Drug–disease associations for OVX836. EMBL-EBI & Wellcome Sanger Institute.
[4]
SEC EDGAR — Osivax company filings. U.S. Securities and Exchange Commission.

Details

Drug Info

Quick Facts

Modality: Biologic[2]
Highest Phase: Phase 2[1]
Company: OOsivax

OVX836

Status by Indication[3][1]

Competitive Landscape

Trials by Indication[1]

Influenza4 trials

Intranasal Administration1 trial

Immune Response1 trial

References

Drug Info

Quick Facts

Related News